NCT03967938View on ClinicalTrials.gov

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Advanced Cancers Harbouring Mutations in HRG
Interventions
DRUG

Olaparib Oral Capsule

Olaparib tablets 300mg twice daily

Trial Locations (1)

1090

UZ Brussel, Brussels

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Kom Op Tegen Kanker

OTHER

lead

AZ-VUB

OTHER